Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 17, 2003
Event: Disclosure of findings from the Mother Infant Rapid Intervention at Delivery (MIRIAD) study conducted by the Centers for Disease Control and Prevention (CDC).
Key Financial Metrics
This filing is a current report regarding a specific event and does not contain financial statements. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The report discloses a material non-financial event: The CDC study found that the Company's OraQuick® Rapid HIV-1 Antibody Test provides results faster when used at the point of care compared to use in a laboratory setting.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on September 16, 2003, detailing the study findings. This information is incorporated by reference as Exhibit 99.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text beyond the context of the study results.
Investor Verification Checklist
- Review the full text of the press release dated September 16, 2003 (Exhibit 99) for detailed study methodology and implications.
- Verify the regulatory status and market adoption potential of point-of-care testing versus laboratory settings for HIV-1 antibodies.
- Monitor subsequent filings for any financial impact resulting from the study's findings.